LAS VEGAS--(BUSINESS WIRE)--Jan. 13, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today, the new FDA guidelines for early phases of drug development are expected to make it easier for Samaritan to manufacture small quantities of compounds for Phase I trials. The FDA's new guidance is intended to streamline drug development by facilitating short-term human studies, using sub-therapeutic doses to reveal mechanisms of action, pharmacokinetic, and the pharmacodynamic properties of a drug that will help Samaritan to select the most promising drugs to develop out of a family of drugs. Dr. Greeson, CEO of Samaritan Pharmaceuticals, stated, "We see these new less restrictive guidelines as most beneficial to small baby Biotechs with limited resources so we welcome these guidelines. The FDA estimates that work done to prepare a request to allow human testing of an experimental drug, currently costs $500,000 to $1 million, and Biotechs can test thousands of drugs only to bring a few to human trials." Dr. Greeson went on to say, "We believe Samaritan has an incredibly hot pipeline, and although early stage, we have found each of our indications has at least one promising drug that could bring incredible rewards to our shareholders."
